Lyra’s transmucosal therapeutic system, now being evaluated in a clinical study, is designed to directly target tissues that are difficult or impossible to access with existing therapies.
Our first product candidate is designed to address chronic rhinosinusitis (CRS), which affects about 27 million – 11% of adults – in the U.S., and has no approved pharmaceutical treatments.
We are working to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.
July 8, 2019
Lyra Therapeutics Adds Laura Edgerly-Pflug as Senior Vice President of Technical Operations